Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

Phase 4

Completed

Conditions: Influenza
Healthy

Interventions: Biological: FluMist Quadrivalent (2017-2018)
Biological: FluMist trivalent (2015-2016)
Biological: FluMist Quadrivalent (2015-2016)

Registration Number: NCT03143101

Lead Sponsor: MedImmune LLC

Brief Summary: This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the previous A/H1N1 strain that was included in the vaccine in the 2015-2016 influenza season.

Detailed Description: This randomized, double-blind, multi-center study will enroll approximately 200 children 24 to less than (\<) 48 months of age. Participants will be randomized in a 1:1:1 ratio to receive two doses of either FluMist quadrivalent 2017-2018, FluMist quadrivalent 2015-2016 formulation, or FluMist trivalent 2015-2016 formulation.

Participants will be screened within 30 days prior to randomization. Randomization will be stratified according to whether the participant ever received prior influenza vaccination. Approximately 50% of the participants will not have been previously vaccinated. All participants will receive two doses of investigational product on Study Days 1 and 28, and followed for a 28-day follow-up period after each dose. Blood and nasal samples will be collected and safety evaluations perfomed.

The duration of participants participation is approximately 2 to 3 months. The study will be conducted during the influenza "off-season" in the US. After completion of the study all participants will be offered and strongly encouraged to receive an inactivated influenza vaccine approved for use in the US for the 2017-2018 influenza season.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 200

Inclusion Criteria

Age 24 months to < 48 months of age
Healthy by medical history and physical examination or presence of stable underlying chronic medical condition for which hospitalization has not been required in the previous year

Key

Exclusion Criteria

History of allergic disease or reactions likely to be exacerbated by any component of the investigational product
Acute illness or evidence of significant active infection (including fever >= 100.4 degrees Fahrenheit (38.0 degrees Celsius) at randomization
History of asthma or history of recurrent wheezing
Any known immunosuppressive condition or immune deficiency disease
Current or expected receipt of immunosuppressive medications within a 28 day window around vaccination
Use of aspirin or salicylate-containing medications within 28 days prior to randomization or expected receipt thru 28 days after vaccination
Use of antiviral agents with activity against influenza viruses within 48 hours prior to first dose of investigational product or anticipated use of such agents through the end of the study follow-up period
Receipt of any non-study seasonal influenza vaccine within 90 days of Dose 1 or planned receipt of non-study seasonal influenza vaccine prior to 28 days after last vaccination
Receipt of immunoglobulin or blood products within 90 days before randomization into the study or expected receipt during study participation
Known or suspected mitochondrial encephalomyopathy
History of Guillian-Barre syndrome
Administration of intranasal medications within 10 days prior to randomization, for expected receipt through 10 days after administration of each dose of investigational product

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
FluMist Quadrivalent (2017-2018)	FluMist Quadrivalent (2017-2018)	Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10\^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were the new A/H1N1 (A/Slovenia/2903/2015), A/H3N2 (A/New Caledonia/71/2014), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
FluMist trivalent (2015-2016)	FluMist trivalent (2015-2016)	Participants will receive intranasal spray of 0.2 milliliter (mL) (total dose in both nostrils) FluMist trivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10\^7±0.5 fluorescent focus units (FFU) of each vaccine strain. Strains included in the trivalent vaccine were: A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), and B/Phuket/3073/2013 (B/Yamagata-lineage).
FluMist Quadrivalent (2015-2016)	FluMist Quadrivalent (2015-2016)	Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10\^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With B/Yamagata HAI Antibody Seroconversion Rate at Day 28	Day 28	Seroconversion rate is defined as \>= 4-fold rise from baseline in B/Yamagata HAI antibody titer. Percentage of participants with \>= 4-fold rise in B/Yamagata HAI antibody titer at Day 28 is reported.
Percentage of Participants With A/H3N2 HAI Antibody Seroconversion Rate at Day 28	Day 28	Seroconversion rate is defined as \>= 4-fold rise from baseline in A/H3N2 HAI antibody titer. Percentage of participants with \>= 4-fold rise in A/H3N2 HAI antibody titer at Day 28 is reported.
Percentage of Participants With A/H3N2 HAI Antibody Seroconversion Rate at Day 56	Day 56	Seroconversion rate is defined as \>= 4-fold rise from baseline in A/H3N2 HAI antibody titer. Percentage of participants with \>= 4-fold rise in A/H3N2 HAI antibody titer at Day 56 is reported.
Percentage of Participants With A/H1N1 Hemagglutination Inhibition (HAI) Antibody Seroconversion Rate at Day 28	Day 28	Seroconversion rate is defined as at least (\>=) 4-fold rise from baseline in A/H1N1 HAI antibody titer. Percentage of participants with \>= 4-fold rise in A/H1N1 HAI antibody titer at Day 28 is reported. Comparative statistical analysis was planned only for 'FluMist Quadrivalent (2015-2016)' and 'FluMist Quadrivalent (2017-2018)' arms.
Percentage of Participants With B/Victoria HAI Antibody Seroconversion Rate at Day 28	Day 28	Seroconversion rate is defined as \>= 4-fold rise from baseline in B/Victoria HAI antibody titer. Percentage of participants with \>= 4-fold rise in B/Victoria HAI antibody titer at Day 28 is reported.
Percentage of Participants With B/Victoria HAI Antibody Seroconversion Rate at Day 56	Day 56	Seroconversion rate is defined as \>= 4-fold rise from baseline in B/Victoria HAI antibody titer. Percentage of participants with \>= 4-fold rise in B/Victoria HAI antibody titer at Day 56 is reported.
Percentage of Participants With B/Yamagata HAI Antibody Seroconversion Rate at Day 56	Day 56	Seroconversion rate is defined as \>= 4-fold rise from baseline in B/Yamagata HAI antibody titer. Percentage of participants with \>= 4-fold rise in B/Yamagata HAI antibody titer at Day 56 is reported.
Percentage of Participants With A/H1N1 HAI Antibody Seroconversion Rate at Day 56	Day 56	Seroconversion rate is defined as \>= 4-fold rise from baseline in A/H1N1 HAI antibody titer. Percentage of participants with \>= 4-fold rise in A/H1N1 HAI antibody titer at Day 56 is reported. Comparative statistical analysis was planned only for 'FluMist Quadrivalent (2015-2016)' and 'FluMist Quadrivalent (2017-2018)' arms.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Strain-specific Nasal Immunoglobulin A (IgA) Seroconversion Rate From Baseline Through Days 28 and 56	Days 28 and 56	Seroconversion rate is defined as \>= 2-fold rise from baseline in strain speciific nasal IgA antibody titer. Percentage of participants with \>= 2-fold rise in strain speciific nasal IgA antibody titer at Days 28 and 56 are reported for this outcome.
Percentage of Participants With Any Solicited Symptoms	Day 1 through Day 14 after Dose 1 (Day 1 dose) and Dose 2 (Day 28 dose)	Solicited symptoms included fever by any route (temperature \>= 100.4 degrees Fahrenheit), runny/stuffy nose, sore throat, cough, headache, generalized muscle aches, lethargy or tiredness/weakness, and decreased appetite.
Percentage of Participants Who Shed Vaccine Virus by Formulation, Strain, Dose Number, and Baseline Serostatus as Measured by Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR)	Days 2, 3, 4, 5, and 7 after Dose 1 (Day 1 dose) and on Days 2, 4, and 6 after Dose 2 (Day 28 dose)	Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used to measure viral shedding from the nasopharyngeal swabs. Percentage of participants who shed virus are reported.
Number of Days of Vaccine Virus Shedding by Formulation, Strain, Dose Number, and Baseline Serostatus as Measured by qRT-PCR	Days 2, 3, 4, 5, and 7 after Dose 1 (Day 1 dose) and on Days 2, 4 and 6 after Dose 2 (Day 28 dose)	Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used to measure viral shedding from the nasopharyngeal swabs. Number of days of virus shedding are reported.
Viral Titer by Day, Strain, Dose Number, and Baseline Serostatus as Measured by qRT-PCR	Day (D) 2, D3, D4, D5, and D7 after Dose 1 (D1 dose) and on D2, D4 and D6 after Dose 2 (D28 dose)	Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used to measure viral titer from the nasopharyngeal swabs. Viral titers are reported.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)	Day 1 through Day 28 after Dose 1 (Day 1 dose) and Dose 2 (Day 28 dose)	An Adverse Event (AE) is any unfavourable and unintended sign, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. A serious adverse event (SAE) is an AE that results in death, initial or prolonged inpatient hospitalization, life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or an important medical event. TEAEs and TESAEs are defined as AEs and SAEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug.
Percentage of Participants With Strain-specific Neutralizing Antibody Seroconversion Rates From Baseline Through Days 28 and 56 by Baseline Serostatus	Days 28 and 56	Seroconversion rate is defined as \>= 4-fold rise from baseline in strain specific microneutralizing antibody titer. Baseline microneutralization values of less than or equal to (\<=) 10 were considered as microneutralization status negative and values greater than (\>) 10 were considered microneutralization positive. Percentage of participants with \>= 4-fold rise in strain specific neutralizing antibody titer at Days 28 and 56 are reported.
Percentage of Participants With Any Post Dose Strain-specific Antibody Response	Days 28 and 56	Strain specific antibody response defined as \>= 4-fold increase in HAI antibodies or \>= 4-fold increase in neutralizing antibodies or \>= 2-fold increase in IgA antibodies.